Phentolamine mesylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for phentolamine mesylate and what is the scope of patent protection?
Phentolamine mesylate
is the generic ingredient in four branded drugs marketed by Septodont Holding, Hikma, Precision Dose Inc, Novartis, and Famygen Life Sci, and is included in five NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Phentolamine mesylate has twenty-three patent family members in sixteen countries.
There are three drug master file entries for phentolamine mesylate. Five suppliers are listed for this compound.
Summary for phentolamine mesylate
International Patents: | 23 |
US Patents: | 6 |
Tradenames: | 4 |
Applicants: | 5 |
NDAs: | 5 |
Drug Master File Entries: | 3 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 16 |
Patent Applications: | 1,555 |
Drug Prices: | Drug price trends for phentolamine mesylate |
What excipients (inactive ingredients) are in phentolamine mesylate? | phentolamine mesylate excipients list |
DailyMed Link: | phentolamine mesylate at DailyMed |
Recent Clinical Trials for phentolamine mesylate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Alberta | Phase 4 |
Cairo University | Phase 3 |
University of Alberta | N/A |
Pharmacology for phentolamine mesylate
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for phentolamine mesylate
Anatomical Therapeutic Chemical (ATC) Classes for phentolamine mesylate
US Patents and Regulatory Information for phentolamine mesylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | REGITINE | phentolamine mesylate | INJECTABLE;INJECTION | 008278-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hikma | PHENTOLAMINE MESYLATE | phentolamine mesylate | INJECTABLE;INJECTION | 040235-001 | Mar 11, 1998 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for phentolamine mesylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for phentolamine mesylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2762153 | ⤷ Sign Up | |
Australia | 2019366451 | ⤷ Sign Up | |
Brazil | 112021007725 | ⤷ Sign Up | |
Japan | 6335927 | ⤷ Sign Up | |
Mexico | 2021004708 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.